Free Trial

Milestone Pharmaceuticals (NASDAQ:MIST) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Milestone Pharmaceuticals logo with Medical background
Remove Ads

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) released its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.04), Zacks reports.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.93 on Thursday. The company has a market cap of $102.92 million, a price-to-earnings ratio of -2.38 and a beta of 1.83. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The stock's 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.79. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.

Check Out Our Latest Stock Report on Milestone Pharmaceuticals

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

See Also

Earnings History for Milestone Pharmaceuticals (NASDAQ:MIST)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Milestone Pharmaceuticals Right Now?

Before you consider Milestone Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.

While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last
Best ETFs for Spring 2025: Strong and Steady Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads